Loading...
Loading...
LUMO| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.2M |
| Operating Expense | 11.0M |
| Operating I/L | -10.9M |
| Other Income/Expense | 0.4M |
| Interest Income | 0.2M |
| Pretax | -10.4M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -10.4M |
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for rare diseases. Their lead therapeutic candidate, LUM-201, is an oral growth hormone secretagogue ibutamoren currently in Phase 2 clinical trial for pediatric growth hormone deficiency and other rare endocrine disorders.
